EUVIMEDEUVIMED entdecken
Crossref

The Tumor-Derived Exosomes Enhanced Bevacizumab across the Blood–Brain Barrier for Antiangiogenesis Therapy against Glioblastoma

Liuxiang Chu, Yuchen Sun iD, Xiaohu Tang, Xinliu Duan, Yanyan Zhao, Hangyu Xia, Lixiao Xu, Peng Zhang iD, Kaoxiang Sun, Gangqiang Yang, Aiping Wang

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.4c01227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Liuxiang Chu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacol…. Hauptthemen laut MEDLINE: Glioblastoma, Blood-Brain Barrier, Exosomes, Bevacizumab. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Yantai University, Natural Science Foundation of Shandong Province, Youth Innovation Team Plan of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody therapy has become a mature cancer treatment strategy, but only one antibody drug, bevacizumab (BEV) has been approved to treat glioblastoma (GBM). The natural blood-brain barrier (BBB) significantly limits the penetration of therapeutic antibodies into the brain. In this study, an antibody delivery platform based on exosomes (EXOs) has been developed, which can cross the BBB and effectively enter the brain tissue to deliver BEV for safe and effective GBM therapy. In vitro experiments have shown that EXO-BEV could efficiently penetrate the BBB and significantly inhibit the migration of endothelial cells. Biodistribution studies in vivo have revealed that EXO serves as an effective carrier for transporting a higher concentration of BEV across the BBB into the brain. Furthermore, in vivo antiglioma experiments have illustrated that the introduction of EXO-BEV into the brain can improve the degeneration of pathological tissues, increase the apoptosis of tumor cells, and significantly extend the survival time of the model animals. All of the results suggested that EXO-BEV could cross the BBB, thereby enhancing the apoptosis of tumor cells and mitigating angiogenesis in GBM. In conclusion, this innovative platform for antibody delivery emerges as a highly promising therapeutic strategy for the clinical treatment of GBM and other neurological disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBlood-Brain BarrierExosomesBevacizumabBrain NeoplasmsAngiogenesis InhibitorsAnimalsHumansMiceCell Line, TumorXenograft Model Antitumor AssaysMice, NudeApoptosisNeovascularization, PathologicTissue DistributionAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

angiogenesisbevacizumabblood−brain barrierexosomesglioblastoma

Substanzen

BevacizumabAngiogenesis InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Ya…
  • Yantai Laishan Fourth People's Hospital, Yantai, Shandong 264036, PR China.
  • State Key Laboratory of Long-Acting and Targeting Drug Delivery System, Shandong Luye Pharmaceutical Co., Ltd, Yantai, Shandong 264003, PR China.

ORCID-Profile: Yuchen Sun, Peng Zhang

Förderung

  • Yantai University
  • Natural Science Foundation of Shandong Province
  • Youth Innovation Team Plan of Shandong Province

Zitieren

APA

Chu, L., Sun, Y., Tang, X., Duan, X., Zhao, Y., Xia, H., Xu, L., Zhang, P., Sun, K., Yang, G., & Wang, A. (2025). The Tumor-Derived Exosomes Enhanced Bevacizumab across the Blood–Brain Barrier for Antiangiogenesis Therapy against Glioblastoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01227

Vancouver

Chu L, Sun Y, Tang X, Duan X, Zhao Y, Xia H, et al. The Tumor-Derived Exosomes Enhanced Bevacizumab across the Blood–Brain Barrier for Antiangiogenesis Therapy against Glioblastoma. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01227

BibTeX
@article{Chu2025,
  author = {Chu, Liuxiang and Sun, Yuchen and Tang, Xiaohu and Duan, Xinliu and Zhao, Yanyan and Xia, Hangyu and Xu, Lixiao and Zhang, Peng and Sun, Kaoxiang and Yang, Gangqiang and Wang, Aiping},
  title = {The Tumor-Derived Exosomes Enhanced Bevacizumab across the Blood–Brain Barrier for Antiangiogenesis Therapy against Glioblastoma},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.4c01227}
}
Kostenlos starten →